At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 39 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
In Brief
A Early Phase 1 clinical trial evaluating Pembrolizumab for Gynecologic Neoplasms and 4 related conditions. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecologic Neoplasms, Epithelial Ovarian Cancer, Uterine Endometrial Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJun 2016
Primary CompletionJan 2019
Study CompletionJan 2022
TodayJul 2026
First PostedApr 5, 2016
Enrollment StartJun 1, 2016
Primary CompletionJan 31, 2019
Study CompletionJan 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.2 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab 200mg IV